Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)

Stopped Study stopped early after review of safety and efficacy demonstrated efficacy proof-of-concept and need for dose reduction.

Conditions

• Primary Biliary Cirrhosis (PBC)

Interventions

• DRUG: Placebo Comparator
• DRUG: Experimental: Seladelpar 50 mg
• DRUG: Experimental: Seladelpar / MBX-8025 200 mg

Sponsor

Gilead Sciences